ALSO NOTED: Tsumura returns rights to hypertension drug; FDA announces Perrigo recall; BioMarin files NDA for Orapred ODT; and

> Tsumura and Dainippon Pharmaceutical have returned the development and marketing rights to the hypertension drug lercanidipine hydrochloride back to Italy's Recordati. Report

> The FDA has announced a voluntary recall of the infant oral meds made by Perrigo. Pain and cough relief medications distributed with a 1.6ML syringe were recalled because the syringe was not properly marked for dispensing small doses of the treatments. Release

> BioMarin Pharmaceutical of Novato, California, has filed an NDA for Orapred ODT, new formulation of prednisolone that is billed as "convenient and easy to administer." Release

> India's Wockhardt has received FDA permission to market a copycat form of GSK's Ceftin in the US. Story

> Princeton, New Jersey-based Pharmacopeia has raised $8.47 million in a private placement of stock. Release

> UCB Japan and Daiichi have reinforced their marketing pact on Zyrtec. Story

And Finally… Researchers say that Vitamin E has simply failed to live up to its promise to prevent illness. Feature

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.